Abstract
With a pair of deals worth more than US$1.7 B, AstraZeneca has taken steps to strengthen and expand its immuno-oncology portfolio, partnering with Innate Pharma for the co-development and commercialisation of the Phase II anti-NKG2A antibody IPH2201 and out-licensing its immune checkpoint inhibitor MEDI4736 (durvalumab) to Celgene for development in haematological malignancies. AstraZeneca also plans to test the two assets in combination in solid tumours, adding to the company’s broad programme of combination trials in immuno-oncology.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
